The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -257,820 | -70,128 |
| Depreciation and amortization | 1,023 | 2,013 |
| Amortization of debt issuance costs and debt discount | 0 | 0 |
| Non-cash operating lease cost | 185 | 357 |
| Loss on debt extinguishment, net | -1,103 | - |
| Stock-based compensation | 3,256 | 6,593 |
| (gain) loss on derivative liability | -58,357 | -1,966 |
| Financing costs and allocated expense for financial instruments at fair value | 3,091 | 4,057 |
| In-process research and development expense | 510 | 4,916 |
| Transaction costs expensed related to semnur business combination | 140,000 | - |
| Change in fair value of debt and liability instruments | 22,031 | 14,480 |
| Change in fair value of equity investments | -8,282 | - |
| Change in fair value of digital assets | -4,702 | - |
| Allowances for expected credit losses | 0 | - |
| Other | 98 | 77 |
| Accounts receivables, net | -4,826 | -9,675 |
| Inventory | -1,378 | 88 |
| Prepaid expenses and other | -5,357 | -1,466 |
| Other long-term assets | 0 | 0 |
| Accounts payable | 4,497 | 6,856 |
| Accrued payroll | -1,238 | 128 |
| Accrued expenses | 14,295 | 599 |
| Accrued rebates and fees | 20,441 | 30,423 |
| Operating lease liability | 180 | 343 |
| Other long-term liabilities | 4 | 10 |
| Net cash proceeds from operating activities | 8,230 | 13,057 |
| Acquisition consideration paid in cash for romeg intangible asset acquisition | 150 | 300 |
| Purchase of equity securities | 0 | - |
| Cash paid for in-process research and development, net | 0 | 200 |
| Purchase of convertible promissory note from denali | 2 | 48 |
| Net cash used for investing activities | -152 | -548 |
| Proceeds from issuance of shares under standby equity purchase agreements and atm sales agreement | 0 | 0 |
| Proceeds from issuance of revolving facility | 0 | 0 |
| Proceeds from issuance of fsf deposit | 0 | 0 |
| Repayment of revolving facility | 0 | 0 |
| Repayment of oramed note | 0 | 0 |
| Repayment of convertible debentures | 0 | 0 |
| Repayment of tranche b notes principal and interest | 7,093 | 8,874 |
| Cash consideration paid in connection with the repurchase of penny warrants | 13,000 | - |
| Payments on purchased revenue liability | 1,217 | 1,156 |
| Transaction costs paid in connection with share repurchase | 300 | 696 |
| Proceeds from issuance of shares under direct offerings | 0 | 0 |
| Payments of direct offering issuance costs | 0 | 0 |
| Payments of debt issuance costs | 71 | - |
| Excise tax paid in connection with share repurchase | 151 | 709 |
| Proceeds from semnur business combination | 33 | - |
| Transaction costs paid related to semnur business combination | 0 | - |
| Proceeds from exercise of december 2024 rdo warrants | 10,237 | - |
| Payments of deferred transaction costs related to semnur business combination | - | 263 |
| Proceeds from stock options and warrants exercised and espp | 0 | 17 |
| Payments in lieu of fractional shares for reverse stock split | 0 | -1 |
| Net cash used for financing activities | -11,299 | -11,682 |
| Net change in cash, cash equivalents and restricted cash | -3,221 | 827 |
| Cash and cash equivalents at beginning of period | 3,272 | - |
| Cash and cash equivalents at end of period | 878 | - |
Scilex Holding Co (SCLXW)
Scilex Holding Co (SCLXW)